Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose Climbing Trial of Anlotinib Plus Pemetrexed/Docetaxel in the Second-line Treatment of Advanced Gene Negative Non-squamous Non-small Cell Lung Cancer

NCT03566576 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT03566576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03566576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose Climbing Trial of Anlotinib Plus Pemetrexed/Docetaxel in the Second-line Treatment of Advanced Gene Negative Non-squamous Non-small Cell Lung Cancer
Lead sponsor
Fujian Cancer Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
July 1, 2018
Completion date
October 1, 2018
Enrollment
18 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer